Peri-Implantitis
Conditions
Brief summary
This study evaluates the efficacy of 1% local metformin gel in deep periimplant pockets of type 2 diabetes mellitus patients. Half of the participants will receive 1% metformin gel with manual debridement while the other half will receive a placebo with manual debridement.
Detailed description
Metformin is an oral hypoglycemic drug categorized under biguanide and are considered the most efficient agents widely used in the treatment of type 2 diabetes mellitus.The general clinical benefits observed in therapy with MF seem to be greater than expected. They induce osteoblast cells to promote early bone formation through AMP kinase (AMPK) activity. Moreover, in a recent in vitro study, MF facilitated in the proliferation of MG63 osteoblast like cells. Thus, their action in stimulating bone formation has justified their use in the treatment of perimplantitis.
Interventions
DRUG1% local metformin gel
After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
PROCEDUREPlacebo
Sponsors
King Saud University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Type 2 diabetes mellitus patients. * Patients with peri-implantitis
Exclusion criteria
* History of any other systemic diseases * Cigarette smokers * Smokeless tobacco users * Patients who underwent scaling in the last 1 year * Patients who took antibiotics in tje past 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Marginal bone loss | 6 months | Marginal bone loss will be assessed on digital radiographs on calibrated computer screen. |
| Peri-implant prpbing depth | 6 months | Will be measured with UNC-15 periodontal probe from crest of the gingival margin to the base of the peri-implant probing depth. |
Outcome results
None listed